Connect with us

Technology

Brainomix Completes £14M ($18M) Series C Round to Advance Its Transformative AI Imaging Technology in Healthcare

Published

on

University of Oxford spinout accelerates commercial expansion in the US of its innovative stroke AI imaging solution, with its demonstrated impact on vital treatmentsFunding will also support clinical uptake of its breakthrough solution in lung fibrosis

OXFORD, England and CHICAGO, March 20, 2025 /PRNewswire/ — Brainomix, a company pioneering AI-powered imaging tools in stroke and lung fibrosis, today announced the completion of a £14M ($18M) Series C investment round. The round is co-led by prominent healthtech investors that include existing investors, Parkwalk Advisors, the UK’s largest growth EIS fund manager, and the Boehringer Ingelheim Venture Fund (BIVF), along with new investor Hostplus via the IP Group Hostplus Innovation Fund. Hostplus is a leading Australian industry superannuation (pension) fund with over AUD$120 billion in funds under management. The round was supported by LifeSci Capital.

A spinout from the University of Oxford, Brainomix now operates in more than 20 countries globally, including the US. It has pioneered the development of an AI platform, Brainomix 360 Stroke, that automates validated imaging biomarkers to improve both diagnosis and treatment decisions. Brainomix is the established European market leader, with a NICE-endorsed technology that has been deployed to more than 300 hospitals, having benefitted more than 1.5M patients.

The company has demonstrated a unique ability to impact treatment rates, with results showing that Brainomix 360 Stroke was associated with an additional 50% increase in the number of patients receiving mechanical thrombectomy, a life-changing stroke treatment reducing disability.

This new investment will enable Brainomix to accelerate its commercial expansion into the US, where the company has recently secured ten FDA clearances. Fresh funding will also support Brainomix to advance its portfolio of AI-powered technology in new areas, facilitating faster diagnosis and increasing access to life-saving treatments. Having grown to a company of more than 75 staff, Brainomix plans to expand both its Oxford-based operations and global commercial team.

Brainomix has applied its AI expertise to lung fibrosis, with the development and FDA clearance of its Brainomix 360 e-Lung technology to accurately predict the progression of the disease. The company has an ongoing partnership with Boehringer Ingelheim, the global leader in lung fibrosis treatments, to evaluate the real-world impact of e-Lung to improve the identification and access to treatment for people with progressive lung fibrosis.

Dr Michalis Papadakis, CEO and Co-Founder at Brainomix, said: “We would like to thank all the investors that participated, including Parkwalk and Boehringer Ingelheim Venture Fund for their continued support, and welcome Hostplus, all of whom recognize the transformative impact that our technology can have on treatment for stroke and lung fibrosis patients. We will continue to harness our position and experience as a European market leader to achieve broad success in the US, helping improve patient care and access to life-changing therapies.”

John Pearson, Chief Investment Officer at Parkwalk, said: “The potential for AI-powered platforms in healthcare to revolutionise diagnosis and treatment decisions is clear. Brainomix has successfully demonstrated its platform imaging software is able to deliver both significant societal impact and strong growth for investors. Parkwalk is excited to continue supporting a company that is creating comprehensive solutions to critical needs and implementing them at scale.”

Dr Oliver Reuss, Investment Manager of the Boehringer Ingelheim Venture Fund (BIVF) and Director of the Brainomix Board, said:  “Brainomix has demonstrated an unparalleled track record of successfully delivering AI solutions into stroke clinical practice, and they are now doing it again in lung fibrosis. As a strategic investor with a shared vision to enhance care for lung disease, we believe Brainomix has the potential to improve the identification and access to treatment for people with lung fibrosis.”

Please watch our video here Brainomix Series C Funding – Dr Michalis Papadakis on Vimeo

Notes to Editors

About Brainomix
Brainomix specializes in the creation of AI-powered software solutions to enable precision medicine for better treatment decisions in stroke and lung fibrosis. With origins as a spinout from the University of Oxford, Brainomix is an expanding commercial-stage company with offices in the UK, Ireland and the USA, and operations in more than 20 countries. A private company, backed by leading healthtech investors, Brainomix has innovated award-winning imaging biomarkers and software solutions that have been clinically adopted in hundreds of hospitals worldwide. Its first product, the Brainomix 360 stroke platform, provides clinicians with the most comprehensive stroke imaging solution, driving increased treatment rates and improving functional independence for patients.

To learn more about Brainomix and its technology visit www.brainomix.com, and follow us on Twitter, LinkedIn and Facebook.

Contacts
Jeff Wyrtzen, Chief Marketing & Business Development Officer
jwyrtzen@brainomix.com
M +44 (0)7927 164210
T +44 (0)1865 582730

Media Enquiries 
Charles Consultants
Christopher Gardner
chris@cgcomms.onmicrosoft.com
M +44 (0)7956 031077

About Parkwalk 
Parkwalk is the largest growth EIS fund manager, backing world-changing technologies emerging from the UK’s leading universities and research institutions. With £500m of assets under management, it has invested in over 180 companies across its award-winning Parkwalk Opportunities and Knowledge Intensive EIS Funds, as well as the enterprise and innovation funds Parkwalk manages for the Universities of Cambridge, Oxford, Bristol and Imperial College. 

For further information visit: parkwalkadvisors.com  

Media Enquiries 
Portland
Pauline Guénot
Pauline.guenot@portland-communications.com
+44 (0)7841 196889

About IP Group Hostplus Innovation Fund
IP Group is the leading investor in university originated deep-tech companies in Australia and the UK. The Group pioneered a unique approach to developing intellectual property into valuable deep-tech companies.  

In Australia and New Zealand, IP Group manages the $435m IP Group Hostplus Innovation Fund.  IP Group works in close partnership with major universities to identify ground-breaking technologies which have the most promising commercial potential. IP Group, which is listed on the Main Market of the London Stock Exchange under the symbol IPO, has a strong track record of success and its portfolio comprises holdings in early stage to mature businesses across life sciences and technology. https://www.ipgroupanz.com/

Media contact:
Craig Regan, Primary Communication on +61 (0) 408 448 527 or craig@primarycommsgroup.com.au

About Boehringer Ingelheim Venture Fund GmbH
The Boehringer Ingelheim Venture Fund (BIVF), established in 2010, is dedicated to investing in groundbreaking biotechnology companies that are at the forefront of therapeutic and digital innovations, aiming to advance biomedical research. With a commitment to revolutionizing the standard of care, the BIVF fosters long-term partnerships with scientists and entrepreneurs. The BIVF’s focus is on nurturing disease-modifying therapeutic concepts and facilitating their clinical application. The BIVF prioritizes the translation of first-in-class concepts that address significant medical needs in fields such as oncology, immunology, regenerative medicine, neurodegeneration, infectious diseases, and digital health technologies. These innovative concepts often encompass novel platform technologies designed to tackle targets and diseases that were previously considered untreatable.

With a fund volume of EUR 350 million, the BIVF operates as an evergreen fund, continually reinvesting to fuel its mission. The partners of the BIVF gain from the fund’s deep expertise in drug discovery & development, translational science, and management, along with access to a network of experts within the Boehringer Ingelheim organization. Currently, the BIVF supports a diverse portfolio of over 40 companies, leveraging its extensive experience to drive progress in healthcare.

For additional information, please visit boehringer-ingelheim-venture.com.

Video: https://www.youtube.com/watch?v=TiujKeHvwzU
Photo: https://mma.prnewswire.com/media/2645475/MichalisPapadakis_CEO_Brainomix.jpg

 

View original content:https://www.prnewswire.co.uk/news-releases/brainomix-completes-14m-18m-series-c-round-to-advance-its-transformative-ai-imaging-technology-in-healthcare-302406209.html

Continue Reading

Technology

Wulcea Elevates Consumer Trust in Heated Apparel Through Multi-National Safety Certifications and Rigorous Technical Testing

Published

on

By

NEW YORK, Oct. 31, 2026 /PRNewswire/ — As smart heated clothing gains broader adoption, consumers are paying closer attention to the safety and reliability of the technology behind these products. Wulcea, a brand specializing in graphene-powered heated apparel, combines its flexible GrapheneNano™ heating technology with documented safety compliance and durability testing for its heating components and battery systems.

“Trust in smart heated apparel goes beyond warmth—it comes down to confidence in battery safety and heating element reliability,” said John C, Founder of Wulcea. “Our goal is to give users peace of mind through certified technical standards.”

Advanced Graphene Heating Elements Supported by Global Standards

At the core of Wulcea’s thermal architecture is its GrapheneNano™ heating technology. Engineered to eliminate garment stiffness, Wulcea integrates flexible graphene elements that deliver balanced warmth across key upper-body zones while preserving natural garment drape and full freedom of movement.

Wulcea supports its heating components with applicable compliance documentation for major markets. These include CE and FCC compliance documentation addressing relevant electrical and electromagnetic compatibility requirements, as well as PSE compliance for applicable products in Japan. RoHS compliance further addresses restrictions on specified hazardous substances in applicable electrical and electronic components.

Multi-Certified Battery System for Dependable Power

To power its heating elements, Wulcea pairs its heated apparel with rechargeable battery systems designed for convenient everyday use. Featuring a compact design and housed in dedicated interior pockets, the batteries provide portable power while maintaining a streamlined garment profile and comfortable fit.

Wulcea backs its battery options with comprehensive third-party accreditations. UL certification demonstrates that the battery system has been evaluated against recognized power bank safety requirements, covering key areas such as overcharge protection, short-circuit protection, and thermal safety. The battery systems are also supported by applicable CE and FCC compliance documentation, addressing relevant regulatory requirements for electrical and electromagnetic compatibility.

For daily handling and travel, RoHS compliance validates that the battery system meets stringent global standards for material safety. The battery models have also undergone applicable UN 38.3 testing, supporting compliance with international requirements for lithium battery transportation.

Real-World Durability and Practical Usability

Component compliance forms Wulcea’s foundation, but reliability is defined by real-world performance. Built for high-flex endurance, Wulcea’s flexible graphene heating elements are tested through 10,000 active flexing cycles to maintain steady thermal output through repeated bending and everyday body movement.

Everyday convenience is equally essential. Built for hassle-free care, Wulcea’s heating elements withstand 100 machine-wash cycles under standard care guidelines, maintaining internal conductivity and structural stability under repeated laundering.

Integrated NTC temperature sensors provide thermal monitoring and are designed to stop heating if temperatures exceed 131°F (55°C). Combined with runtime of up to 10 hours on the low setting and a discreet interior control button, these features support practical everyday use in cold-weather conditions.

Aligning Technical Standards with Everyday Warmth

By combining graphene-based heating technology with documented battery safety compliance and durability testing, Wulcea continues to focus on the technical foundations of dependable heated apparel. This approach reflects the brand’s emphasis on bringing together safety considerations, practical functionality, and everyday comfort for cold-weather use.

View original content to download multimedia:https://www.prnewswire.com/news-releases/wulcea-elevates-consumer-trust-in-heated-apparel-through-multi-national-safety-certifications-and-rigorous-technical-testing-302925554.html

SOURCE Wulcea

Continue Reading

Technology

NIDS Co., Ltd. Confirms CES 2027 Participation, Pursues Expansion of Global Supply Chain for Environmental Sensors

Published

on

By

Company introduced optical and gas sensors at SEDEX and is strengthening its composite sensor business for robotics, home appliances, automotive, and smart building applications

SEOUL, South Korea, Oct. 31, 2026 /PRNewswire/ — Environmental sensor manufacturer NIDS Co., Ltd. has confirmed its participation in CES 2027 and is moving to expand its global business-to-business (B2B) supply chain. Building on its experience supplying sensors to domestic and international home appliance and automotive companies, the company aims to secure overseas customers and extend its applications into smart building HVAC and robotics.

NIDS recently participated in the Korea Semiconductor Industry Association’s Sensor Pavilion at SEDEX 2026, held at COEX in Seoul, where it introduced its next-generation sensor modules. The company said the exhibition allowed it to raise awareness of its technology among domestic home appliance and electronic component industry professionals and to lay the groundwork for collaboration in the sensor field.

The company will use CES 2027 as its next stage. NIDS plans to firm up discussions on sensor module supply with global home appliance makers, HVAC specialists, and robotics companies. It aims to extend the industry contacts gained at the domestic exhibition overseas and to convert product introductions into actual supply opportunities.

Founded in 2000, NIDS develops and manufactures environmental sensors and air quality management solutions. According to the company, it has supplied more than 10 million sensors cumulatively to domestic and international companies, including Dyson, Samsung Electronics, and Hyundai Motor. Drawing on this supply track record, the company intends to showcase its precision sensing technology and mass-production capabilities to overseas customers.

Its main products include particulate matter sensors, optical gas sensors based on non-dispersive infrared (NDIR) technology, composite environmental sensors, and electronic nose sensor modules. The particulate matter sensors measure PM1.0, PM2.5, and PM10, while the gas sensor lineup targets carbon dioxide (CO₂), carbon monoxide (CO), and other gases. The electronic nose is used for detecting everyday odors, gas leaks, and fires. The company said it designs the core components required for air quality measurement in-house and has a system in place to mass-produce 5 million units annually.

The area where NIDS will expand development and supply going forward is next-generation composite sensor modules. The company has been pursuing a sensor business that responds to industry-specific demand in home appliances, automotive, and smart building HVAC, and is now concentrating its capabilities on markets such as robotics, industrial safety, and odor detection based on this technology. Building on its experience supplying individual components, NIDS plans to continue developing and supplying, on a B2B basis, modules that handle multiple types of environmental data.

The company will also highlight its sensor product lineup and its newly developed ultra-compact MEMS sensor technology at the exhibition. NIDS plans to introduce its optical and gas sensor lineup along with examples of their application in actual air quality management systems. By explaining both the measurement functions of its components and its experience operating sensors for finished-product services, the company aims to broaden the scope of partnership discussions.

NIDS explained that, because it owns its precision sensors, it can control sensor sensitivity and tune algorithms to suit the system in which they are applied. Drawing on this technical operating experience, the company plans to pursue partnerships with customers and to promote its business capabilities extending from sensor components to air quality and odor management and industrial safety management.

NIDS will also leverage its existing branch network in its overseas market development. Through its overseas bases in the United States, Japan, and China, the company plans to widen its touchpoints with buyers and seek new supply opportunities in conjunction with its CES participation. Its goal is to generate export results by combining exhibition participation with its local networks.

The company intends to keep expanding the global supply of sensor components as a core pillar of its business. Building on the supply experience accumulated in home appliances and automotive, it will broaden its partners to robotics, HVAC, and smart buildings, and respond to industry-specific air quality measurement demand through the development of next-generation modules.

“We plan to continue expanding the development and B2B supply of next-generation composite sensor modules needed across a range of industries, including home appliances, automotive, and smart building HVAC,” NIDS said.

View original content to download multimedia:https://www.prnewswire.com/news-releases/nids-co-ltd-confirms-ces-2027-participation-pursues-expansion-of-global-supply-chain-for-environmental-sensors-302925577.html

SOURCE NIDS Co., Ltd.

Continue Reading

Technology

Towards Buddha Co., Ltd. and ICP DAS Showcase iTLC Intelligent Traffic Control Solutions at APTA 2026 in Chicago

Published

on

By

Advancing smart intersection technologies and expanding international market opportunities through strategic collaboration

CHICAGO, Oct. 31, 2026 /PRNewswire/ — Towards Buddha Co., Ltd., an overseas distributor of the iTLC Intelligent Traffic Control System, joined its technology partner ICP DAS at APTA 2026 TRANSform & EXPO in Chicago, USA, to showcase the iTLC-9000 Series and its applications in intelligent traffic management.

The exhibition highlighted innovative traffic control technologies designed to support reliable, secure, and integrated smart intersection operations, while providing opportunities to connect with international transportation professionals and explore emerging market needs.

Innovative Traffic Control Solutions

Under the theme “Innovative Traffic Control System,” the exhibition featured the iTLC-9000 Series, highlighting four key capabilities: modular and redundant design, secure networking, traffic signal integration, and active alert systems.

These technologies are designed to support system reliability, communication security, and efficient traffic infrastructure management, addressing the evolving requirements of modern intelligent transportation systems.

As cities worldwide continue to modernize transportation infrastructure, integrated and adaptable traffic control solutions are becoming increasingly important for smart intersection development.

Strengthening International Market Connections

As an overseas distributor of iTLC solutions, Towards Buddha Co., Ltd. plays an important role in connecting traffic control technologies with international markets.

During APTA 2026, Towards Buddha Co., Ltd. and ICP DAS engaged with transportation professionals, system integrators, and industry representatives to introduce iTLC technologies, exchange industry insights, and explore potential business opportunities.

“APTA 2026 provided a valuable platform to connect with the global transportation industry,” said a representative of Towards Buddha Co., Ltd. “Together with ICP DAS, we look forward to expanding international awareness of iTLC solutions and developing new opportunities in intelligent traffic control.”

Looking Ahead

Building on its participation at APTA 2026, Towards Buddha Co., Ltd. will continue collaborating with ICP DAS to promote iTLC solutions, strengthen international partnerships, and explore new opportunities in the global intelligent transportation market.

About Towards Buddha Co., Ltd.

Towards Buddha Co., Ltd. is an overseas distributor of the iTLC Intelligent Traffic Control System, focused on international market development and connecting advanced traffic control technologies with transportation industry needs.

Media Contact

Towards Buddha Co., Ltd.
Contact: Michael Chen
Email: Towardsbuddhaincorporation@gmail.com
Website: https://www.towardsbuddha.com 

SOURCE Towards Buddha Co., Ltd.

Continue Reading

Trending